Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for co…
This bill requires the HHS Secretary to withdraw the currently effective mifepristone REMS (risk evaluation and mitigation strategy) and, within 90 days of enactment, reapprove a REMS identical to the version the Secretary approved in June 2011. It bars the Secretary from approving any REMS for mifepristone that differs from that June 2011 strategy and mandates that a REMS be required for mifepristone.
Access vs. safety framing: liberals emphasize reduced access and harm to patients, conservatives emphasize restored safety/controls.
Relative to its intended legislative type, this bill is a substantive policy measure that is precise in key directives (specific statutory amendments, defined timelines, and explicit remedies) but is limited in explanatory context, fiscal and enforcement scaffolding, and accountability mechanisms.
This bill requires the HHS Secretary to withdraw the currently effective mifepristone REMS (risk evaluation and mitigation strategy) and, within 90 days of enactment, reapprove a REMS identical to the version the Secretary approved in June 2011.
It bars the Secretary from approving any REMS for mifepristone that differs from that June 2011 strategy and mandates that a REMS be required for mifepristone.
The bill creates a federal private cause of action against specified “covered entities” (telehealth providers, pharmacies, or any person who knowingly imports or transports mifepristone in violation of 18 U.S.C. 1462) for bodily injury or harm to mental health attributable to use of imported or transported mifepristone, allowing compensatory and punitive damages and attorneys’ fees; that remedy becomes effective 90 days after enactment.
On content alone, the bill is narrow in subject but high in controversy. It prescribes a rollback to an earlier agency regime, constrains agency discretion, creates a federal private right of action with punitive damages, and bans importation of a drug tied to abortion access. Those features make it contentious, prone to lengthy floor fights and litigation, and harder to enact in a bicameral legislature that requires broad agreement in at least one chamber. The relatively short, targeted statutory changes make procedural passage possible in a chamber aligned on the policy, but the combined legal, regulatory, and political obstacles reduce overall enactment likelihood.
Relative to its intended legislative type, this bill is a substantive policy measure that is precise in key directives (specific statutory amendments, defined timelines, and explicit remedies) but is limited in explanatory context, fiscal and enforcement scaffolding, and accountability mechanisms.
Access vs. safety framing: liberals emphasize reduced access and harm to patients, conservatives emphasize restored safety/controls.
These are examples from the analysis, not a ranked list of the most-affected groups.
Access vs. safety framing: liberals emphasize reduced access and harm to patients, conservatives emphasize restored safety/controls.
A mainstream liberal/left-leaning observer would likely view this bill as a restrictive measure that reduces access to medication abortion and intervenes in FDA regulatory discretion.
They would be concerned the mandated reinstatement of an older REMS and the import ban will make it harder for patients—especially low-income, rural, and marginalized people—to obtain a standard, evidence-based treatment.
They would also see the federal tort provision and import ban as mechanisms that could chill telemedicine and pharmacy dispensing and increase legal exposure for providers who expand access.
A centrist/moderate would see elements of legitimate safety oversight in reinstating a REMS but would be concerned about mandating a specific historic REMS and about the broader legal and access consequences.
They would weigh possible patient-safety improvements against potential disruptions to care, the risk of politicizing FDA decisions, and the legal uncertainty created by the new federal tort and a near-total import ban.
A centrist would likely want clearer definitions, carve-outs, and a requirement that policy be driven by up-to-date evidence.
A mainstream conservative observer would likely view the bill favorably as restoring stricter federal controls over mifepristone distribution, deterring cross-border or mail-order access that bypasses state law, and creating legal accountability for entities that knowingly import or ship the drug in violation of federal law.
They would see reinstating the 2011 REMS and banning importation by mail as pro-safety and pro-enforcement measures to protect patients.
Some conservatives might nonetheless want even stronger criminal or enforcement provisions, but overall this bill aligns with priorities to restrict abortion access and control distribution channels.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is narrow in subject but high in controversy. It prescribes a rollback to an earlier agency regime, constrains agency discretion, creates a federal private right of action with punitive damages, and bans importation of a drug tied to abortion access. Those features make it contentious, prone to lengthy floor fights and litigation, and harder to enact in a bicameral legislature that requires broad agreement in at least one chamber. The relatively short, targeted statutory changes make procedural passage possible in a chamber aligned on the policy, but the combined legal, regulatory, and political obstacles reduce overall enactment likelihood.
The bill has not accumulated any surfaced votes yet.
Access vs. safety framing: liberals emphasize reduced access and harm to patients, conservatives emphasize restored safety/controls.
On content alone, the bill is narrow in subject but high in controversy. It prescribes a rollback to an earlier agency regime, constrains a…
Relative to its intended legislative type, this bill is a substantive policy measure that is precise in key directives (specific statutory amendments, defined timelines, and explicit remedies) but is limited in explanat…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.